Real-world and trial-based cost-effectiveness analysis of bevacizumab in HER2-negative metastatic breast cancer patients: a study of the Southeast Netherlands Breast Cancer Consortium

R. J. W. van Kampen, B. L. T. Ramaekers, D. J. A. Lobbezoo, M. de Boer, M. W. Dercksen, F. van den Berkmortel, T. J. Smilde, A. J. van de Wouw, F. P. J. Peters, J. M. G. van Riel, N. A. J. B. Peters, V. C. G. Tjan-Heijnen, M. A. Joore*

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

Original languageEnglish
Pages (from-to)238-246
Number of pages9
JournalEuropean Journal of Cancer
Volume79
DOIs
Publication statusPublished - Jul 2017

Keywords

  • Metastatic breast cancer
  • Bevacizumab
  • Cost-effectiveness analysis
  • Real-world
  • Trial based
  • Cost-benefit analysis
  • RANDOMIZED PHASE-III
  • 1ST-LINE TREATMENT
  • PLUS DOCETAXEL
  • PACLITAXEL
  • WOMEN

Cite this